CA
SLRN

CHI Advisors’s ACELYRIN SLRN Stock Holding History

CHI Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$23M Sell
2,262,990
-400,816
-15% -$8.51M 9.12% 4
2023
Q2 		$55.7M Buy
+2,663,806
New +$54.5M 16.89% 2

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

CHI Advisors's SLRN Position: Q3 2023 in Review

CHI Advisors reduced its ACELYRIN (SLRN) stake by 15% in Q3 2023, selling an estimated $8.51M and leaving 2,262,990 shares worth $23M. The position accounts for 9.12% of the portfolio, ranked #4.

CHI Advisors first reported a position in SLRN in Q2 2023 and has held it in 2 quarters since. The position peaked at $55.7M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

  • CHI Advisors held 2,262,990 shares of ACELYRIN worth $23M as of Q3 2023.
  • CHI Advisors sold 400,816 ACELYRIN shares in Q3 2023, an estimated $8.51M.
  • ACELYRIN made up 9.12% of CHI Advisors's portfolio in Q3 2023, its #4 holding.
  • CHI Advisors first reported a position in ACELYRIN in Q2 2023 and has held it in 2 quarters since.
  • CHI Advisors's ACELYRIN position peaked at $55.7M in Q2 2023.
  • 101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.